Complexities in defining remission in rheumatic diseases

Clinical and Experimental Rheumatology

Volumn 24, Issue 6 SUPPL. 43, 2006, Pages

  Pincus, Theodore ^a   Kavanaugh, Arthur ^b   Aletaha, Daniel ^c   Smolen, Josef ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Hietzing Hospital   (Austria)

Author keywords

Remission; Rheumatic diseases; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD SALT; PENICILLAMINE;

ADL DISABILITY; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE FREE INTERVAL; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL STATUS; HUMAN; JOINT SWELLING; LOW DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; HUMANS; RECURRENCE; REMISSION INDUCTION; RHEUMATIC DISEASES;

EID: 33750687558     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. EMERY P, SALMON M: Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 944-7.
2. WEINBLATT ME: Rheumatoid arthritis: Treat now, not later! (editorial). Ann Intern Med 1996; 124: 773-4.
3. PINCUS T, STEIN CM, WOLFS F: "No evidence of disease" in rheumatoid arthritis using methotrexate in combination with other drugs: A contemporary goal for rheumatology care? Clin Exp Rheumatol 1997; 15: 591-6.
4. PREVOO MLL, van GESTEL AM, van't HOF MA, van RIJSWIJK HM, van de PUTTS LBA, van RIEL PLCM: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 1101-5.
5. SVENSSON B, SCHAUFELBERGER C, TELEMAN A, THEANDER J: Remission and response to early treatment of RA assessed by the disease activity score. Rheumatology 2000; 39: 1031-6.
6. JANTTI J, KAARELA K, KAUTIAINEN H, ISOMAKI H, AHO K: Radiographic remission in seropositive rheumatoid arthritis. A 20-year follow-up study. Clin Exp Rheumatol 2001; 19: 573-6.
7. PINCUS T, SOKKA T: Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses? J Rheumatol 2001; 28: 1723-34.
8. MÖTTÖNEN T, HANNONEN P, KORPELA M et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
9. BALSA A, CARMONA L, GONZALEZ-ALVARO I, BELMONTE MA, TENA X, SANMARTI R: Value of disease activity score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 40-6.
10. GOSSEC L, DOUGADOS M, GOUPILLE P et al.: Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004; 63: 675-80.
11. PAULUS HE: Defining remission in rheumatoid arthritis: what is it? does it matter? J Rheumatol 2004; 31: 1-4.
12. PINCUS T, SOKKA T, KAVANAUGH A: Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S50-S56.
13. MAKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year followup study. J Rheumatol 2005; 32: 796-800.
14. van der HEIJDE D, KLARESKOG L, BOERS M et al.: Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64: 1582-7.
15. ALETAHA D, WARD MM, MACHOLD KP, NELL VPK, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis. Arthritis Rheum 2006; 2625.
16. ALETAHA D, SMOLEN JS: Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol. In press.
17. EBERHARDT K, FEX E: Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 2006; 1324.
18. FRANSEN J, CREEMERS MCW, van RIEL PLCM: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2006; 1252.
19. LANDEWE R, van der HEIJDE D, van der LINDEN S, BOERS M: Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006; 637.
20. MAKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2006; 1410.
21. MOLENAAR ET, VOSKUYL AE, DINANT HJ, BEZEMER PD, BOERS M, DIJKMANS AC: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2006; 36.
22. STEIN CA, BINGHAM III CO: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2006; 185.
23. van der HELM-VAN MIL ARM, BREEDVELD F, HUIZINGA TWJ: Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther 2006; 8.
24. VERSTAPPEN SMM, van ALBADA-KUIPERS GA, BIJLSMA JWJ et al.: A good response to DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2006; 38.
25. WOLFS F, HAWLEY DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-52.
26. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines of the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46.
27. PINCUS T, O'DELL JR, KREMER JM: Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy. Ann Intern Med 1999; 131: 768-74.
28. CALLAHAN LF, PINCUS T: Mortality in rheumatic diseases. Arthritis Care Res 1995; 8: 229-41.
29. PINCUS T, SOKKA T: Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. Rheum Dis Clin N Am 2004; 30: 725-51.
30. OLSEN NJ, STEIN CM: New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-79.
31. LANDEWE R, VAN der HEIJDE D: Radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S63-S68.
32. URAMOTO KM, MICHET CJ JR, THUMBOO J, SUNKU J, O'FALLON WM, GABRIEL SE: Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50.
33. STEEN VD: Scleroderma renal crisis. Rheum Dis Clin N Am 2003; 315-33.
34. PINCUS T, SOKKA T: Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol 2005; 23: S1-S9.
35. GOLDSMITH CH, SMYTHE HA, HELEWA A: Interpretation and power of pooled index. J Rheumatol 1993; 20: 575-8.
36. ARNEIT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
37. PINALS RS, MASI AT, LARSEN RA et al.: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
38. PINCUS T: The American College of Rheumatology (ACR) core data set and derivative "patient only" indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S109-S113.
39. FRANSEN J, van RIEL PLCM: The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23: S93-S99.
40. ALETAHA D, SMOLEN J: The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S100-S108.
41. BELLAMY N: The WOMAC knee and hip osteoarthritis indices: development, validation, globalization and influence on the development of the AUSCAN hand OA indices. Clin Exp Rheumatol 2005; 23: S148-S153.
42. LAM GKW, PETRI M: Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23: S120-S132.
43. ZOCHLING J, BRAUN J: Assessment of ankylosing spondylitis. Clin Exp Rheumatol 2005; 23: S133-S141.
44. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-8.
45. SEO P, MIN Y, HOLBROOK JT et al.: Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trail (WGET). Arthritis Rheum 2005; 52: 2168-78.
46. KAVANAUGH A, CASSELL S: The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol 2005; 23: S142-S147.
47. MIKKELSEN WM, DODGE H: A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, community health study. Arthritis Rheum 1969; 12: 87-91.
48. O'SULLIVAN JB, CATHCART ES: The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 1972; 76: 573-7.
49. ROPES MW, BENNETT GA, COBB S, JACOX RF, JESSAR RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175-6.
50. HUIZINGA TW, AMOS CI, van der HELM-VAN MIL AHM et al.: Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52:3433-8.
51. van AKEN J, van BILSEN JHM, ALLAART CF, HUIZINGA TWJ, BREEDVELD FC: The Leiden Early Arthritis Clinic. Clin Exp Rheumatol 2003; 21: S100-S105.
52. van AKEN J, van DONGEN H, LE CESSIE S, ALLAART CF, BREEDVELD FC, HUIZINGA TWJ: Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006; 65: 20-25.
53. HUIZINGA TWJ, MACHOLD KP, BREEDVELD FC, LIPSKY PE, SMOLEN JS: Criteria for early rheumatoid arthritis. From Bayes' Law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002; 46: 1155-1159.
54. HARRISON BJ, SYMMONS DPM, BRENNAN P, BARREIT EM, SILMAN AJ: Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996; 35: 1096-100.
55. QUINN MA, GREEN MJ, MARZO-ORTEGA H et al.: Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 2003; 48: 3039-45.
56. STEIN CM, PINCUS T: Placebo-controlled studies in rheumatoid arthritis: Ethical issues. Lancet 1999; 353: 400-3.
57. PUOLAKKA K, KAUTIAINEN H, MOTTONEN T, HANNONEN P, KORPELA M: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 36-41.
58. TEN WOLDE S, BREEDVELD FC, HERMANS J et al.: Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347: 347-52.
59. KREMER JM, RYNES RI, BARTHOLOMEW LE: Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med 1987; 82: 781-6.
60. OKA M, VAINIO U: Effect of pregnancy on the prognosis and serology of rheumatoid arthritis. Acta Rheumatol Scand 1966; 12: 47-52.
61. NELSON JL, HUGHES KA, SMITH AG, NISPEROS BB, BRANCHAUD AM, HANSEN JA: Maternal-fetal disparity in HLA Class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 1993; 329: 466-71.
62. Veterans Administration Cooperative Study on Antihypertensive Agent: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213: 1143-50.
63. WILT TJ, BLOOMFIELD HE, MACDONALD R et al.: Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2006; 1427.
64. The diabetes control and complications trial research group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
65. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14-21.
66. CHOI HK, HERNÁN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
67. PINCUS T, CALLAHAN LF: Prognostic markers of activity and damage in rheumatoid arthritis: Why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease. Br J Rheumatol 1995; 34: 196-9.
68. ALETAHA D, SMOLEN J, WARD MM: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-92.
69. ZOCHLING J, BRAUN J: Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S83-S87.
70. CHUNG CP, THOMPSON JL, KOCH GG, AMARA I, STRAND V, PINCUS T: Are American College of Rheumatology 50% response criteria (ACR50) superior to 20% criteria (ACR20) to distinguish active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A metaanalysis of discriminant capacities. Ann Rheum Dis 2006; Published online 27 Feb 2006.
71. BENCIVELLI W, VITALI C, ISENBERG DA et al.: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 549-54.
72. GLADMAN DD, UROWITZ MB, GOLDSMITH CH et al.: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-13.
73. SMOLEN JS, STRAND V, CARDIEL M et al.: Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999; 26:504-7.
74. PINCUS T, KAVANAUGH A, SOKKA T: Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S2-S11.
75. SMOLEN JS, HAN C, BALA M et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 1020-30.
76. WELLS GA, BOERS M, SHEA B, BROOKS PM, SIMON LS, STRAND CV: Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 2016-24.